"Nick brings over three decades’ experience to his supervision of the practice, personally taking on work in biotech and medical devices. He is an astute operator in the field of immunology, especially the T-cell sphere. He acted for an anonymous entity to revoke Cellectis’s patent relating to CAR T cells for allogeneic transplantation. " - IAM Patent 1000, 2023
"Lee heads the team and works with both biotechnology and medical devices clients, bringing specific expertise in the T cell niche." - IAM Patent 1000, 2022
'Recommended' in IAM Patent 1000, 2021
2022, 2021, 2020, 2016, 2015 and 2014 IP Stars Handbook, Managing IP – ‘IP Star’
2019: The Legal 500 for his work representing Harvard College in its European patent for its gene editing technology CRISPR.
2019: IAM Patent – "a biosciences buff whose EPO advocacy in complex nanotechnology, immunology and diagnostics matters has to be seen to be believed."
2019, 2018 and 2015: Who’s Who Legal: Patents – a World leading patent attorney who "has a 'high profile' in the European patent market, say sources, and is commended for his expertise when it comes to the biotechnology and medical devices sectors" and 'First choice' Nick Lee primarily focuses his practice on prosecution and opposition matters at the European Patent Office, and specializes in the fields of biosciences.
2017: IAM Patent – for his work "fronting the effort to help se-cure protection for Harvard College’s cutting-edge work on the CRISPR/Cas9 gene-editing system".
2016: IAM Patent 1000 – handling of "all worldwide patent drafting and prosecution for bio-tech titan Immunocore’ and his work protecting a multi-purpose platform for using the body’s own defences to target cancer cells".